← All Sponsors
SPONSOR

Santen SAS

Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: Acquired BlepharophimosisMyopia
NCT06514612 Phase 3
Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

Acquired Blepharophimosis
Czechia, France, Germany View Trial →
NCT06912802
Recruiting

Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.

Myopia
Denmark, France, Germany View Trial →